Video

Dr. McLaughlin on Lymphedema in Breast Cancer

Sara McLaughlin, MD, professor of Surgery, Mayo Clinic, discusses the frequency that lymphedema appears in patients with breast cancer and addresses the complications in identifying this after her presentation at the Lynn Sage Breast Cancer Symposium.

Sara McLaughlin, MD, professor of surgery, Mayo Clinic, discusses the frequency that lymphedema appears in patients with breast cancer, as well as addresses the complications in identifying the condition following her presentation at the 2018 Lynn Sage Breast Cancer Symposium.

McLaughlin says their estimations are that 5% of women with a sentinel node biopsy and 20% of women with an axillary node dissection experience lymphedema. This also increases when compound radiation is added to an axillary procedure. In these cases, the rates of lymphedema can nearly double, she explains.

According to McLaughlin, lymphedema may be more common than is currently known in the field. This is because lymphedema does not develop until 3 to 5 years following their treatment. Moreover, most studies do not follow patients this far out, meaning it can often go unreported.

View more from the 2018 Lynn Sage Breast Cancer Symposium

Related Videos
Hope Rugo, MD, FASCO, and Aditya Bardia, MD, MPH, FASCO
Hope Rugo, MD, FASCO, and Aditya Bardia, MD, MPH, FASCO
Yuan Yuan, MD, PhD
Thierry Andre, MD, professor, medical oncology, Sorbonne Université; head, Medical Oncology Department, Saint Antoine Hospital
Sanjay Popat, BSc, MBBS, FRCP, PhD, consultant medical oncologist, The Royal Marsden Hospital; professor, thoracic oncology, the Institute of Cancer Research
Paolo Tarantino, MD
Yuan Yuan, MD, PhD
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School
Angeles A. Secord, MD, MHSc, professor, obstetrics and gynecology, Duke Cancer Institute, discusses findings from the phase 2 PICCOLO trial (NCT05041257) investigating mirvetuximab soravtansine-gynx (Elahere) in patients with recurrent, platinum-sensitive ovarian cancer with high folate receptor alpha (FRα) expression.
Nancy U. Lin, MD, associate chief, Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers, director, Metastatic Breast Cancer Program, director, Program for Patients with Breast Cancer Brain Metastases, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School